Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study
Table 3
Changes in values of Gastrointestinal Symptom Rating Scale (GSRS) and State Trait Anxiety (STAI) between baseline and after 4 weeks of treatment.
Baseline
Treatment
GSRS
Total dimension
Biobran
3.21 ± 0.93
2.60 ± 0.96
<0.001
Placebo
2.93 ± 0.68
2.77 ± 0.75
N.S.
Reflux
Biobran
2.33 ± 1.35
1.71 ± 1.17
0.013
Placebo
1.66 ± 0.90
1.55 ± 0.90
N.S.
Abdominal pain
Biobran
2.33 ± 1.35
1.71 ± 1.17
N.S.
Placebo
1.66 ± 0.90
1.55 ± 0.90
N.S.
Indigestion
Biobran
3.21 ± 0.93
2.60 ± 0.96
N.S.
Placebo
2.93 ± 0.68
2.77 ± 0.75
N.S.
Diarrhea
Biobran
4.88 ± 1.98
3.51 ± 2.02
<0.001
Placebo
4.39 ± 1.59
3.95 ± 1.40
N.S.
Constipation
Biobran
3.87 ± 1.73
3.20 ± 1.67
0.024
Placebo
3.68 ± 1.82
3.28 ± 1.67
N.S.
STAI
State
Biobran
3.21 ± 0.93
2.60 ± 0.96
N.S.
Placebo
2.93 ± 0.68
2.77 ± 0.75
N.S.
Trait
Biobran
3.21 ± 0.93
2.60 ± 0.96
N.S.
Placebo
2.93 ± 0.68
2.77 ± 0.75
N.S.
Values are mean ± SD; No significant changes between Biobran and Placebo.
